OptiBiotix Health (LSE:OPTI) ROCE %: -44.61% (As of Dec. 2025)


What is OptiBiotix Health ROCE %?

OptiBiotix Health LSE:OPTI ROCE % is -44.61% as of Dec. 2025. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OptiBiotix Health's annualized ROCE % for the quarter that ended in Dec. 2025 was -44.61%.

OptiBiotix Health  (LSE:OPTI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OptiBiotix Health ROCE % Related Terms

OptiBiotix Health ROCE % Historical Data

* Premium members only.

The historical data trend for OptiBiotix Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptiBiotix Health ROCE % Chart

OptiBiotix Health Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.04 15.84 -16.55 -25.32 -41.25

OptiBiotix Health Semi-Annual Data
Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.10 -25.17 -29.28 -33.09 -44.61

OptiBiotix Health ROCE % Calculation

OptiBiotix Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-3.132/( ( (9.045 - 0.368) + (6.892 - 0.384) )/ 2 )
=-3.132/( (8.677+6.508)/ 2 )
=-3.132/7.5925
=-41.25 %

OptiBiotix Health's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-3.39/( ( (9.152 - 0.46) + (6.892 - 0.384) )/ 2 )
=-3.39/( ( 8.692 + 6.508 )/ 2 )
=-3.39/7.6
=-44.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -44.61% mean?
OptiBiotix Health (LSE:OPTI) has a ROCE % of -44.61% as of Dec. 2025.
Is OptiBiotix Health's ROCE % too high?
OptiBiotix Health's current ROCE % is -44.61%.
How does OptiBiotix Health's ROCE % compare to VRTX and REGN?
OptiBiotix Health's ROCE % of -44.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. OptiBiotix Health's current ROCE % is -44.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
Based on GuruFocus' analysis, OptiBiotix Health (LSE:OPTI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.30, compared to a current price of £0.06 — trading 78.8% below its estimated fair value. The current ROCE % is -44.61%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For OptiBiotix Health (LSE:OPTI), the current ROCE % is -44.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OptiBiotix Health Business Description

Address Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.